Scope Research and HealthFMV. Healthcare M&A research and independent valuations for 15+ years.
Jun 23, 2026
•
11 min read
Ensemble closes at $12 billion with its old investors still in the room, Simulations Plus goes private at 16.6x EBITDA, and Thurston builds a top-10 DSO out of three companies it already owned.
Jun 16, 2026
16 min read
Humana sells 40% of Gentiva at ~2.3x revenue, a medtech consumables exit at 19x EBITDA, and a deep dive into the intersection of vascular, podiatry, and wound care
Jun 9, 2026
14 min read
The FTC clears AmSurg with divestitures, FONAR's insiders buy the company at 4.3x EBITDA (or less), and LaserAway tests what a scaled medspa platform is actually worth.
Jun 2, 2026
Lilly pivots to vaccines with three deals, a retail-to-vet deal that actually makes sense, and why HCA is buying a college.
May 26, 2026
15 min read
Quorum's nonprofit conversion, Boston Scientific takes a $1.5B flyer on TAVR, and a deep dive into medspas
May 19, 2026
The market repriced the GMR IPO by 36%, lenders took the keys at Affordable Care, and two fairness opinions explain why 7.9x and 23.9x might both be the right answer.
May 12, 2026
12 min read
Knox Lane buys the dip in travel nursing and KKR goes public in EMS, plus a few private duty tidbits
May 5, 2026
A dental deep dive, Lilly's fourth biotech buy in four weeks, and Teleflex finally goes private.
Apr 28, 2026
A $1.1B home health take-private, and why the projections matter more than the multiple.
Apr 21, 2026
10 min read
Avanos Medical take-private at 14.7x EBITDA, and why the headline number is the wrong read.
Apr 14, 2026
8 min read
Healthcare M&A from the filings, not just the press releases. Issue #1 is here.
